Concurrent oral capecitabine chemotherapy

PreclinicalSmall molecule

Concurrent oral capecitabine chemotherapy is one of 6 small molecule programs targeting Hilar Cholangiocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hilar CholangiocarcinomaActive, not recruiting

Hilar CholangiocarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Hilar Cholangiocarcinoma

#DrugCompanyPhaseTrials

Adrucil

EElorac, Inc.

Approved

—2

Photofrin

PPinnacle Biologics Inc.

Beyfortus

1 4

Gemzar

Johnson & Johnson

Phase 2

1 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Preclinical

1 6

Concurrent oral capecitabine chemotherapy

TThe Christie NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

N/ANot yet recruiting

Hilar Cholangiocarcinoma

NCT06434493

Clinical

Trials by Indication[1]

Hilar Cholangiocarcinoma1 trial

Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma

Not yet recruiting·TThe Christie NHS Foundation Trust·N/A·NCT06434493·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Concurrent oral capecitabine chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Concurrent oral capecitabine chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Concurrent oral capecitabine chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Christie NHS Foundation Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe Christie NHS Foundation Trust

Concurrent oral capecitabine chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Hilar Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News